The longitudinal immunologic status of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-infected patients and its association with the clinical outcome are barely known. Thus, we sought to analyze the temporal profiles of specific antibodies, as well as the associations between the antibodies, proinflammatory cytokines, and survival of patients with coronavirus disease 2019 (COVID-19). A total of 1830 laboratory-confirmed COVID-19 cases were recruited. The temporal profiles of the virus, antibodies, and cytokines of the patients until 12 weeks since illness onset were fitted by the locally weighted scatter plot smoothing method. The mediation effect of cytokines on the associations between antibody responses and survival were explored by mediation analysis. Of the 1830 patients, 1435 were detectable for SARS-CoV-2, while 395 were positive in specific antibodies only. Of the 1435 patients, 2.4% presented seroconversion for neither immunoglobulin G (IgG) nor immunoglobulin M (IgM) during hospitalization. The seropositive rates of IgG and IgM were 29.6% and 48.1%, respectively, in the first week, and plateaued within five weeks. For the patients discharged from the hospital, the IgM decreased slowly, while high levels of IgG were maintained at around 188 AU.mL(-1) for the 12 weeks since illness onset. In contrast, in the patients who subsequently died, IgM declined rapidly and IgG dropped to 87 AU.mL(-1) at the twelfth week. Elevated interleukin-6, interleukin-8, interleukin-10, interleukin-1 beta, interleukin-2R, and tumor necrosis factor-alpha levels were observed in the deceased patients in comparison with the discharged patients, and 12.5% of the association between IgG level and mortality risk was mediated by these cytokines. Our study deciphers the temporal profiles of SARS-CoV-2-specific antibodies within the 12 weeks since illness onset and indicates the protective effect of antibody response on survival, which may help to guide prognosis estimation. (C) 2021 THE AUTHORS. Published by Elsevier LTD on behalf of Chinese Academy of Engineering and Higher Education Press Limited Company.
基金:
National Natural Science Foundation of China [81572017]; National Key Research and Development Plan Program of China [2016YFC1302702, 2020YFC0860800]; COVID-19 Plague of the China Association for Science and Technology [20200608CG111311]; Emergency Research Projects for COVID-19 Prevention and Control of the Wuhan Health Commis-sion [EG20M01]
第一作者单位:[1]Huazhong Univ Sci & Technol, Tongji Med Coll, Sch Publ Hlth, Dept Epidemiol & Biostat,Minist Educ,Key Lab Envi, Wuhan 430030, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Liu Li,Chen Heng-Gui,Li Ying,et al.Temporal Profiles of Antibody Responses, Cytokines, and Survival of COVID-19 Patients: A Retrospective Cohort[J].ENGINEERING.2021,7(7):958-965.doi:10.1016/j.eng.2021.04.015.
APA:
Liu, Li,Chen, Heng-Gui,Li, Ying,Li, Huijun,Li, Jiaoyuan...&Cheng, Liming.(2021).Temporal Profiles of Antibody Responses, Cytokines, and Survival of COVID-19 Patients: A Retrospective Cohort.ENGINEERING,7,(7)
MLA:
Liu, Li,et al."Temporal Profiles of Antibody Responses, Cytokines, and Survival of COVID-19 Patients: A Retrospective Cohort".ENGINEERING 7..7(2021):958-965